Related Experiment Video
Updated: May 8, 2026
16:07
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
Tumor necrosis factor-α antagonists: Side effects and their management
1Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian Journal of Dermatology, Venereology and Leprology
|August 27, 2013
Summary
Tumor necrosis factor-alpha (TNF-α) antagonists effectively treat psoriasis but require careful monitoring for adverse effects like infections and malignancies. Understanding these risks is crucial for safe and effective patient management.
Area of Science:
- Immunodermatology
- Rheumatology
- Pharmacology
Background:
- Elevated tumor necrosis factor-alpha (TNF-α) correlates with psoriasis and psoriatic arthritis severity.
- TNF-α antagonists are crucial for moderate-to-severe cases unresponsive or intolerant to conventional therapies.
Purpose of the Study:
- To review known adverse effects and contraindications of TNF-α antagonists in psoriasis.
- To highlight the importance of understanding and managing these risks for safe therapeutic use.
Main Methods:
- Review of known side effects of TNF-α antagonists.
- Discussion of pathomechanisms and management guidelines.
- Comparison of adverse effect profiles in psoriasis versus rheumatoid arthritis and inflammatory bowel disease.
Main Results:
- Common side effects include infusion/injection site reactions, infections (e.g., tuberculosis reactivation), autoantibody formation, drug-induced lupus erythematosus, liver abnormalities, hematological issues, and malignancies.
- Adverse effect profiles may differ in psoriasis patients compared to those with RA or IBD due to differing treatment regimens and comorbidities.
- Long-term studies are needed to fully elucidate risks in psoriasis patients.
Conclusions:
- Careful baseline screening and periodic monitoring are essential for early identification and management of adverse outcomes.
- Effective and safe use of TNF-α antagonists necessitates comprehensive knowledge of their potential side effects and contraindications.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:30Combined Effects of Drugs: Antagonism
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.